Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

Vertex Pharmaceuticals is making waves with its new pain treatment, Journavx, which is experiencing a prescription growth ...

Two excellent candidates are Vertex Pharmaceuticals ( VRTX -1.05%) and Axsome Therapeutics ( AXSM -1.06%). Here's what makes ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Analysts are intrested in these 5 stocks: ( ($SKX) ), ( ($SHOP) ), ( ($FANG) ), ( ($VRTX) ) and ( ($TBCH) ). Here is a ...

Right now, a fantastic tariff safe-haven stock, one that's climbed nearly 70% in three years, is offering investors a great ...

Nutriband's AVERSA(TM) technology is advancing toward commercialization as the first abuse-deterrent transdermal fentanyl patch <li /> Re ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Barclays has nudged Vertex Pharmaceuticals’ price target to $499, despite a mixed bag in its Q1 performance. Vertex saw a 3% ...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter results were weak as it missed estimates for both earnings and sales. The company’s total revenues of $2.77 billion rose 3% year over year, ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...